Baystate Medical Center
Trial Pipeline
A Type I Hybrid Effectiveness-Implementation Trial of MIO
NCT07168642
Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms
NCT07019454
Aim 2 - Conversations Can Save Lives: TALKing About Buprenorphine & Methadone for Opioid Use Treatment Initiation
NCT06527820
Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial
NCT05925634
Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling
NCT05399056
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
NCT05733767
The Role of 4 Different Consent Approaches on a Pilot Study to Increase Cardiac Rehabilitation Attendance
NCT07123480
Exercise Prescription in Cardiac Rehabilitation
NCT03925493
A Home-Based Study to Enhance Activity in Breast Cancer Survivors
NCT02969291
Increasing Use of Publicly Reported Pediatric Quality Data
NCT01784575
Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy
NCT00984100
Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test
NCT00883103
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for Baystate Medical Center Shows
According to the ClinicalTrials.gov registry, Baystate Medical Center is linked to 12 US clinical trials across every stage of research activity. Of those, 6 studies are currently recruiting — about 50% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 42% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Baystate Medical Center reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Baystate Medical Center is Percutaneous Coronary Intervention with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.